CAH

Business Context and Reporting Period

Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 2001 (Fiscal Year 2002).
Business Overview: The Company operates in four segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services.

Key Financial Metrics

Note: Net earnings for the six-month period include a $70.1 million cumulative effect of a change in accounting principle.

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 17% for both the three and six-month periods compared to the prior year, driven by higher sales volume, pharmaceutical price increases, and new customer contracts.
• Margin Compression: Overall gross margin as a percentage of operating revenue decreased to 8.92% (3 months) and 9.08% (6 months) from 9.26% and 9.35% respectively. This was primarily due to a higher mix of lower-margin pharmaceutical distribution business (82% of revenue) and margin declines in the Pharmaceutical Technologies segment.
• Special Charges: Merger-related and integration costs totaled $16.8 million for the quarter and $29.1 million for the six months, compared to $8.0 million and $20.3 million in the prior year periods. These charges reduced net earnings by $10.3 million (quarter) and $17.9 million (six months).
• Accounting Change: The Company adopted SFAS 142, ceasing goodwill amortization effective July 1, 2001. Additionally, revenue recognition for pharmacy automation equipment changed from delivery to installation, resulting in a $70.1 million net-of-tax cumulative effect recorded in the first quarter.
• Cash Flow: Net cash used in operating activities was $947.0 million for the six months ended Dec 31, 2001, compared to $262.4 million used in the prior year. This increase was driven by a $1.96 billion increase in inventories and a $169.7 million increase in trade receivables.

Guidance, Outlook, and Risks

• Future Costs: Management estimates approximately $118.3 million ($73.4 million net of tax) in additional merger-related and integration costs will be incurred in future periods, primarily fiscal 2002 and 2003.
• Legal Proceedings: The Company faces approximately 562 lawsuits regarding natural rubber latex glove sensitization. While significant expenses are probable, the Company believes a substantial portion of liability will be covered by insurance. A settlement regarding insurance reimbursement was reached in October 2001.
• Subsequent Event (Kmart Bankruptcy): Following Kmart's Chapter 11 filing on January 22, 2002, the Company noted that while Kmart represents ~5% of total volume, credit exposure is limited due to a consignment structure where Cardinal retains ownership of inventory. No material financial impact is anticipated.
• Liquidity: The Company maintains adequate capital resources for operations and debt service. Shareholders' equity increased to $5.9 billion, supported by net earnings and employee stock plan investments, partially offset by $115.7 million in share repurchases.

Investor Verification Checklist

• Inventory Build-up: Verify the sustainability of the $2.0 billion increase in inventories and its impact on future working capital requirements.
• Accounting Change Impact: Confirm the long-term effect of the revenue recognition change for automation equipment on future quarterly earnings volatility.
• Merger Integration Costs: Monitor the realization of the estimated $118.3 million in future merger-related expenses.
• Latex Litigation: Track the resolution of the 562 pending latex glove lawsuits and the adequacy of insurance coverage.
• Customer Concentration: Assess the risk exposure to large retail customers (e.g., Kmart) given the recent bankruptcy filing.